Based on the news about the stock in the past five trading days, please predict the rise or fall of the stock in the next trading day. If the stock is predicted to rise in the next trading day, please output [Rise], if the stock is predicted to fall in the next trading day, please output [Decrease].

Date:2018-06-21, Stock:ABBV, The news for the past five days is as follows:
2018-06-14: NEWS1: AbbVie Declares Quarterly Dividend.
2018-06-15: NEWS1: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR.NEWS2: Daily Dividend Report: VICI, WPC, ABBV, BMY, EQR.NEWS3: MARKETS: Here's why stocks are dropping right now.NEWS4: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS5: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS6: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS7: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS8: Pharma Stock Roundup: LLY/AZN Alzheimer&apos;s Drug Fails, MRK&apos;s Keytruda Wins Approvals.NEWS9: 3 High-Yield Stocks at Rock-Bottom Prices.NEWS10: Better Buy: AbbVie Inc. vs. GlaxoSmithKline plc.NEWS11: Analysis: Positioning to Benefit within Canopy Growth, Aurora Cannabis, CannTrust, AbbVie, Cronos Group, and Scotts Miracle-Gro — Research Highlights Growth, Revenue, and Consolidated Results.NEWS12: AbbVie Announces New Undetectable Minimal Residual Disease Data from Phase 3 Relapsed/Refractory Chronic Lymphocytic Leukemia MURANO Trial of Venetoclax in Combination with Rituximab at 23rd European Hematology Association Annual Congress.
2018-06-18: NEWS1: Bristol-Myers Posts Data on Empliciti, China Approves Opdivo.NEWS2: How U.S. tax reform rewards companies that shift profit to tax havens.NEWS3: Today's Research Reports on Trending Tickers: Canopy Growth and AbbVie.
2018-06-19: NEWS1: Agree To Purchase AbbVie At $55, Earn 3.2% Using Options.NEWS2: Agree To Purchase AbbVie At $55, Earn 3.2% Using Options.NEWS3: 8,000 AbbVie Employees Volunteer Across Five Continents During Fifth-Annual "Week of Possibilities".NEWS4: Wired News – AbbVie Presents New Undetectable Minimal Residual Disease Data from Phase-3 MURANO Trial of Venetoclax with Rituximab at 23rd European Hematology Association Annual Congress.NEWS5: 3 Great Reasons to Buy Gilead Sciences.NEWS6: Bristol-Myers Posts Data on Empliciti, China Approves Opdivo.NEWS7: Bristol-Myers Posts Data on Empliciti, China Approves Opdivo.
2018-06-20: NEWS1: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS2: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS3: 5 Experimental New Drugs That Could Be Worth $47 Billion.NEWS4: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS5: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.NEWS6: Forget Johnson & Johnson: Here Are 2 Better Dividend Stocks.

Answer: Decrease